Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice

[1]  R. Casper.  Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. , 2017, Fertility and sterility.

[2]  A. Romano,et al.  Endometrial preparation with Dienogest before hysteroscopic surgery: a systematic review , 2017, Archives of Gynecology and Obstetrics.

[3]  P. Vercellini,et al.  Surgery versus hormonal therapy for deep endometriosis: is it a choice of the physician? , 2017, European journal of obstetrics, gynecology, and reproductive biology.

[4]  Y. Osuga,et al.  Drospirenone reduces inflammatory cytokines, vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) expression in human endometriotic stromal cells. , 2017, Journal of reproductive immunology.

[5]  P. Saunders,et al.  Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium , 2017, Human reproduction.

[6]  A. Soliman,et al.  Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women , 2016, Gynecologic and Obstetric Investigation.

[7]  S. Kim,et al.  Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis , 2016, Obstetrics & gynecology science.

[8]  N. Kapp,et al.  A prospective, open-label, multicenter study to assess the pharmacodynamics and safety of repeated use of 30 mg ulipristal acetate. , 2016, Contraception.

[9]  Y. Katagiri,et al.  Preoperative dienogest to improve the surgical field of view in resectoscopic surgery , 2016 .

[10]  M. Lombès,et al.  Ulipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human Breast Cancer Proliferation and BCl2-L1 Expression , 2015, PloS one.

[11]  E. Marbaix,et al.  In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. , 2015, Fertility and sterility.

[12]  Johannes E. Schindelin,et al.  The ImageJ ecosystem: An open platform for biomedical image analysis , 2015, Molecular reproduction and development.

[13]  L. Matytsina-Quinlan,et al.  Abnormal excessive per vagina (PV) bleeding on Esmya–selective progesterone receptor modulator (SPRM) in a symptomatic patient with uterine fibroid , 2015, BMJ Case Reports.

[14]  A. Baldi,et al.  New evidence in endometriosis. , 2015, The international journal of biochemistry & cell biology.

[15]  I. Osterloh,et al.  Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. , 2015, Fertility and sterility.

[16]  R. Cardiff,et al.  Manual hematoxylin and eosin staining of mouse tissue sections. , 2014, Cold Spring Harbor protocols.

[17]  A. Prentice,et al.  ESHRE guideline: management of women with endometriosis. , 2014, Human reproduction.

[18]  N. Tempest,et al.  Theories on the Pathogenesis of Endometriosis , 2014, International journal of reproductive medicine.

[19]  H. Croxatto,et al.  Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. , 2013, Contraception.

[20]  T. Wakasa,et al.  Efficacy of dienogest in thinning the endometrium before hysteroscopic surgery. , 2013, Journal of minimally invasive gynecology.

[21]  C. Dirksen,et al.  The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey. , 2013, Human reproduction.

[22]  C. A. Huniadi,et al.  The effects of ulipristal on Bax/Bcl-2, cytochrome c, Ki-67 and cyclooxygenase-2 expression in a rat model with surgically induced endometriosis. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[23]  J. Endrikat,et al.  Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study. , 2013, Contraception.

[24]  M. Menger,et al.  Anti-angiogenic treatment strategies for the therapy of endometriosis. , 2012, Human reproduction update.

[25]  T. Faustmann,et al.  Ovulation‐Inhibiting Effects of Dienogest in a Randomized, Dose‐Controlled Pharmacodynamic Trial of Healthy Women , 2012, Journal of clinical pharmacology.

[26]  A. Okamoto,et al.  Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest , 2012, The journal of obstetrics and gynaecology research.

[27]  Katherine E Pelch,et al.  Mouse model of surgically-induced endometriosis by auto-transplantation of uterine tissue. , 2012, Journal of visualized experiments : JoVE.

[28]  A. Schindler,et al.  Effect and safety of high-dose dienogest (20 mg/day) in the treatment of women with endometriosis , 2010, Archives of Gynecology and Obstetrics.

[29]  H. Croxatto,et al.  Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. , 2010, Human reproduction.

[30]  C. Gerlinger,et al.  Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. , 2010, Human reproduction.

[31]  D. Timmerman,et al.  Reply of the Authors: Endometriosis: is laparoscopy justified without previous ultrasonogram and magnetic resonance imaging (MRI)? & High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners , 2010 .

[32]  Avijit Ray,et al.  Isolation of Mouse Peritoneal Cavity Cells , 2010, Journal of visualized experiments : JoVE.

[33]  S. Ferrari,et al.  Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. , 2009, The American journal of pathology.

[34]  L. Hummelshoj,et al.  Life after a diagnosis with endometriosis ‐ a 15 years follow‐up study , 2009, Acta obstetricia et gynecologica Scandinavica.

[35]  Sun‐Wei Guo,et al.  Recurrence of endometriosis and its control. , 2009, Human reproduction update.

[36]  A. Ciavattini,et al.  Expression of Vascular Endothelial Growth Factor (VEGF), Hypoxia Inducible Factor-1α (HIF-1α), and Microvessel Density in Endometrial Tissue in Women With Adenomyosis , 2009, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[37]  P. Ng,et al.  Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model. , 2008, Human reproduction.

[38]  E. Somigliana,et al.  Management of endometriomas in women requiring IVF: to touch or not to touch. , 2008, Human reproduction.

[39]  R. Salvatori,et al.  Sizes of abdominal organs in adults with severe short stature due to severe, untreated, congenital GH deficiency caused by a homozygous mutation in the GHRH receptor gene , 2008, Clinical endocrinology.

[40]  S. Jentsch,et al.  PCNA, the Maestro of the Replication Fork , 2007, Cell.

[41]  D. Mansour.  Use of the new progestogens in contraception and gynaecology , 2006 .

[42]  A. Ferenczy,et al.  Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile. , 2006, Maturitas.

[43]  Dean Sheppard,et al.  Integrin-mediated activation of latent transforming growth factor β , 2005, Cancer and Metastasis Reviews.

[44]  K. Chwalisz,et al.  Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. , 2005, Endocrine reviews.

[45]  Y. Taketani,et al.  Possible Pathophysiological Roles of Mitogen‐Activated Protein Kinases (MAPKs) in Endometriosis , 2004, American journal of reproductive immunology.

[46]  F. Ebling,et al.  Methods for quantifying follicular numbers within the mouse ovary. , 2004, Reproduction.

[47]  Teiji Wada,et al.  Mitogen-activated protein kinases in apoptosis regulation , 2004, Oncogene.

[48]  A. Moo-Young,et al.  Subdermal progestin implant (Nestorone®) in the treatment of endometriosis: clinical response to various doses , 2003, Acta obstetricia et gynecologica Scandinavica.

[49]  M. Simões,et al.  Metoclopramide-Induced Hyperprolactinemia Affects Mouse Endometrial Morphology , 2003, Gynecologic and Obstetric Investigation.

[50]  Y. Kitaoka,et al.  Endometriosis: the pathophysiology as an estrogen-dependent disease , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[51]  Adrian L. Harris,et al.  Association of hypoxia‐inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma , 2002 .

[52]  H. Kanzaki,et al.  The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. , 2001, Molecular human reproduction.

[53]  Chris Albanese,et al.  NF-κB and cell-cycle regulation: the cyclin connection , 2001 .

[54]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[55]  C. Bergeron,et al.  Low incidence of endometrial hyperplasia with acceptable bleeding patterns in women taking sequential hormone replacement therapy with dydrogesterone , 2000, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[56]  Y. Shibutani,et al.  Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. , 1999, European journal of pharmacology.

[57]  B. Evers,et al.  The role of NF-κB/IκB proteins in cancer: implications for novel treatment strategies , 1999 .

[58]  M. Dardenne.  Role of thymic peptides as transmitters between the neuroendocrine and immune systems. , 1999, Annals of medicine.

[59]  V. Kähäri,et al.  Matrix metalloproteinases and their inhibitors in tumour growth and invasion. , 1999, Annals of medicine.

[60]  Takashi Suzuki,et al.  Deficient 17β-Hydroxysteroid Dehydrogenase Type 2 Expression in Endometriosis: Failure to Metabolize 17β-Estradiol , 1998 .

[61]  C. Borner,et al.  Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c , 1998, Nature.

[62]  Kristina Riehemann,et al.  Regulation of NF-κB Activation by MAP Kinase Cascades , 1997 .

[63]  P. Vercellini,et al.  Progestins for symptomatic endometriosis: a critical analysis of the evidence. , 1997, Fertility and sterility.

[64]  P. V. D. Linden.  Theories on the pathogenesis of endometriosis , 1996 .

[65]  T. Douchi,et al.  Relationship Between Sonographic Endometrial Thickness and Progestin‐Induced Withdrawal Bleeding , 1996, Obstetrics and gynecology.

[66]  D. Barlow,et al.  A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosist , 1994 .

[67]  D. Aoki,et al.  Successful Heterotransplantation of Human Endometrium in SCID Mice , 1994, Obstetrics and gynecology.

[68]  R. Shaw.  Treatment of endometriosis , 1992, The Lancet.

[69]  D. Lane,et al.  Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasms , 1990, The Journal of pathology.

[70]  I. Brosens,et al.  Histology and ultrastructure of human endometriotic tissues treated with dydrogesterone (Duphaston). , 1987, European journal of obstetrics, gynecology, and reproductive biology.

[71]  L. Morsink,et al.  Influence of dydrogesterone (6-dehydroretroprogesterone, Duphaston) on ovulation in the rat, rabbit and monkey. , 1971, Acta endocrinologica.

[72]  J. Sampson.  Metastatic or Embolic Endometriosis, due to the Menstrual Dissemination of Endometrial Tissue into the Venous Circulation. , 1927, The American journal of pathology.

[73]  S. Islam,et al.  Histomorphological changes in endometriosis in a patient treated with ulipristal: A case report. , 2017, Pathology, research and practice.

[74]  N. Leyland,et al.  Use of Ulipristal Acetate for the Management of Fibroid-Related Acute Abnormal Uterine Bleeding. , 2016, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[75]  M. Wielgoś,et al.  Application of ulipristal acetate in female patients with uterine fibroids. , 2014, Neuro endocrinology letters.

[76]  Tao Zhang,et al.  Prodrug of green tea epigallocatechin-3-gallate (Pro-EGCG) as a potent anti-angiogenesis agent for endometriosis in mice , 2012, Angiogenesis.

[77]  J. Jensen,et al.  Treatment of Heavy Menstrual Bleeding with the Estradiol Valerate and Dienogest Oral Contraceptive Pill , 2012, Advances in Therapy.

[78]  J. Dungan.  Ulipristal Acetate versus Placebo for Fibroid Treatment Before Surgery , 2012 .

[79]  Oprs Alert.  Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers , 2005 .

[80]  C. Albanese,et al.  NF-kappaB and cell-cycle regulation: the cyclin connection. , 2001, Cytokine & growth factor reviews.

[81]  A. Hernandez,et al.  The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies. , 1999, Surgical oncology.

[82]  H. Sasano,et al.  Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. , 1998, The Journal of clinical endocrinology and metabolism.

[83]  S. Rabbani.  Metalloproteases and urokinase in angiogenesis and tumor progression. , 1998, In vivo.

[84]  Rabbani Sa.  Metalloproteases and urokinase in angiogenesis and tumor progression. , 1998 .

[85]  D. Ferrari,et al.  Regulation of NF-kappa B activation by MAP kinase cascades. , 1997, Immunobiology.

[86]  D. Barlow,et al.  A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. , 1994, Fertility and sterility.

[87]  J. Sampson,et al.  Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity , 1927 .

[88]  M. Matzuk,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Anti-Müllerian Hormone Attenuates the Effects of FSH on Follicle Development in the Mouse Ovary , 2022 .